The American Journal of the Medical Sciences

Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematologic malignancies but faces significant challenges in solid tumors such as breast cancer. A primary obstacle is the immunosuppressive tumor microenvironment (TME), which drives T-cell exhaustion and limits therapeutic efficacy. Lymphocyte-activation gene 3 (LAG-3) is a key mediator of this exhaustion, suppres…

CAR-T cell therapy researchHealth SciencesMedicineOncology
research.ioresearch.io

Sign up to keep scrolling

Create your feed subscriptions, save articles, keep scrolling.

Already have an account?